Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Listing expected on March 18, 2013
http://www.injex.com/share-prospectus-approved
INJEX share prospectus approved by the German Federal Financial Supervisory Authority (BaFin)
Berlin, February 26, 2013 - INJEX Pharma AG is pleased to announce that the German Federal Financial Supervisory Authority (BaFin) today approved the share prospectus of the company. The prospectus is from now on available on the Company's website at www.injex.com.
watch pdf file here: Wertpapierprospekt INJEX Pharma AG
INJEX Pharma aims to achieve a listing on the regulated market of the Frankfurt Stock Exchange (segment General Standard) – an approved prospectus by BaFin is a precondition. A stock exchange listing on the regulated market is delivering increased visibility on the capital markets for the company and is part of the implementation of the growth strategy. The desired listing in General Standard will broaden the shareholder base of the company even more and will make it easier to trade the shares for international investors.
The admission of shares is expected on March 11, 2013 in the regulated market of the Frankfurt Stock Exchange in the General Standard segment. The listing is expected on March 18, 2013. A change of this timetable is still possible. The securities code number of the shares is ISIN: DE000A0STYL7, the WKN number is WKN: A0STYL.
For further information on INJEX Pharma AG and its subsidiaries, please refer to www.injex.com.
For further questions please contact our Investor Relations team directly:
INJEX Pharma AG
Investor Relations Team
t: +49 89 24 41 18 - 223
f: +49 89 24 41 18 - 499
ir@injex.com
Today, Sammy Sosa visited Injex Pharma in Berlin...
http://www.injex.de/sammy-sosa-besucht-injex-zentrale
INJEX Pharma AG doubled the office space in the Tristan Building at Buckower Damm 114. Further employees are engaged at this days. The new reception can be found on the second floor
http://www.injex.com/injex-pharma-ag-doubled-office-space
Preliminary figures first Half of 2012 and Preliminary figures third quarter
October 2012
http://www.injex.com/investor-timetable
I don't know if there will be ADR or something like that!
The next step in the USA will be the NASDAQ listing. (october or november)
I also don't know how the advertisement will look like.
I will let myself be surprised. :)
@Rymankoly
The Manager of 21 MEDICAL TECHNOLOGIES, LLC is Samuel Sosa!
http://ccfcorp.dos.state.fl.us/scripts/cordet.exe?action=DETFIL&inq_doc_number=L12000110027&inq_came_from=NAMFWD&cor_web_names_seq_number=0000&names_name_ind=&names_cor_number=&names_name_seq=&names_name_ind=&names_comp_name=21MEDICALTECHNOLOGIES&names_filing_type=
You know Sammy Sosa? ;)
This should also clear the question of the advertising character and the budget.
INJEX Pharma AG signs exclusive Distribution Agreement for USA / Minimum Purchase of 70,000 INJEX30 Systems and 25,000 SHIREEN Beauty Kits in the first year
INJEX Pharma AG / Key word(s): Contract
04.09.2012 / 15:37
INJEX Pharma AG signs exclusive Distribution Agreement for USA / Minimum Purchase of 70,000 INJEX30 Systems and 25,000 SHIREEN Beauty Kits in the first year
INJEX Pharma AG ISIN: DE000A0STYL7
Berlin, 04 September 2012
Berlin - Newly founded '21 Medical Technologies LLC.,' (21 MT) located in Fort Lauderdale, Florida, will exclusively market and distribute INJEX30 Systems in the United States. INJEX30 syringes without a needle may be used in multiple medical, cosmetic and anesthetic applications and marketed via traditional pharmaceutical and emerging life science modalities. INJEX30 targeted disease states and delivery systems include diabetes, local and dental anesthetics, allergy and fertility treatments, vaccinations, erectile dysfunction and growth hormones. '21 MT' is a perfect partner in the US and it's an exciting time for INJEX Pharma AG as we continue to execute on our global mission while simultaneously introducing the SHIREEN Beauty Kit utilizing a 'Poring method' in the United States.' Andy Rösch, CEO INJEX Pharma AG.
The signed distributor agreement includes a minimum volume of 70,000 INJEX30 Systems, 25,000 SHIREEN Beauty Kits and 300,000 SHIREEN Fluid Units. The First shipment will commence during the month of September.
'Product launches in the United States must be carefully orchestrated across many modalities including direct to the consumer. The United States' healthcare industry appears to be in early stages of its transformation which presents an opportune time to align our innovative technology with a 'High profile personality.' '21 MT' has the ability to raise immediate awareness for both INJEX30 Systems and SHIREEN Beauty Kits through its media reach and seasoned team of professionals. We look forward to working closely with '21 MT' as they prepare to deploy significant resources across modalities. This multi-faceted approach will be necessary to build brand awareness with an emphasis on 'service excellence.' This agreement is a 'Home run' for the end users who will benefit from a syringe delivery system without a needle.' Sylwin Grinman, Director International Sales and Marketing at INJEX Pharma AG.
'We are excited to begin marketing our innovative 'Poring method' with SHIREEN Beauty Kits in the world's biggest beauty market. '21 MT' was founded with an appreciation for challenges when dealing with big markets and we are comfortable '21 MT' will exceed distribution expectations and establish new benchmarks for 'service excellence' in this industry. We will be increasing our production capacities in the short-term and developing necessary logistical contingencies to meet future demand. '21 MT' will consummate this agreement in the days ahead, with payments on the way, triggering exclusivity, as terms for initial shipments are met. Shortly thereafter, we expect to conduct a press conference with 21 Medical Technologies LLC, elaborating on our vision, steps for executing in the US and defining details related to this agreement.' Andy Rösch, CEO INJEX Pharma AG.
Contact:
Andy Rösch
CEO
INJEX Pharma AG
Buckower Damm 114
12349 Berlin
Tel.: +49-3053096768
andy.roesch@injex.com
www.injex.com
Sylwin Grinman
Managing Director
INJEX Pharma USA
1922 NE 119 RD
North Miami Beach - FL - 33181
USA
Tel.: +1-7865121963
sylwin@injex.com
End of Corporate News
source:
http://www.dgap.de/news/corporate/injex-pharma-signs-exclusive-distribution-agreement-for-usa-minimum-purchase-injex-systems-and-shireen-beauty-kits-the-first-year_42269_731650.htm
In my opinion there ist no real competition between injex and antares.
Only the other User was talking about that.
Antares has much more in the pipeline and other fields like injex.
The only overlapping thing is the needle free system. Antares was the developer of PharmaJet? I can't remember the right name of the system right now. And that's all...
I think the main product of Injex will be the needle free Shireen poring method in the Beauty Market.
In October or November there will be the first sales figures... until that everything is speculation ;)
I was also thinking about an investment in Antares, but the takeover rumors are making me skeptic at the moment. Maybe in a few months...
best regards
blackleguan
@Rymankoly
No they aren't...
Jim Fukushima was Owner and CEO at this point!
Now Injex is back in Germany. In the Year 2000 the Market wasn't big enough to establish the needle free system.
But now in 2012 some people of the team from 2000 (with the special know-how) are back to place Injex succesfully on the market.
With the innovation of the Shireen system in the Beauty market Injex has a good chance to establish on the market...
We will see...
Shareholder Newsletter 22/08/12
INJEX Pharma AG has successfully re-launched the needle free injection technology and obtained approvals in important markets
New beauty product SHIREEN will significantly contribute to profitable growth of the company
Dear Shareholder,
With a small team we completed the takeover of the entire worldwide business of INJEX Pharma GmbH. In February 2012, we merged all rights and assets into a corporate shell listed at the open market of the Frankfurt Stock Exchange. We started to set-up a strong professional team.
We managed to install a quality management system according to the ISO 13485 standard. Based on the higher performance level in quality management and product management we were able to speed up national registrations in several important countries. Today, the company has obtained CE Approval, FDA 510(k) registration, the Canadian medical device license, registration in Brazil and a couple of other markets. We also expect to get approval from China in the short term.
INJEX Pharma AG has signed exclusive agreements with dedicated partners worldwide. Some of them started already marketing and sales activities – others will start very soon after the national registration.
The INJEX30 system has moved into the focus of the pharmaceutical industry again. The research and development division of INJEX Pharma AG has some very promising projects in the pipeline and new funding will be used to build up a strong R&D team and to intensify R&D activities.
10 years ago, the market for needle free technology was small and a lot of companies failed to commercialize the technology. Today, this market is larger and has a very high potential. Also medication has changed. Today, the doses of drugs injected are much smaller and this opens up the market for needle free injection, which was limited by the dosage size 10 years ago.
With our new product SHIREEN we are entering the beauty market worldwide. The new poring method is an offer, in particular, to women, who are interested in the rejuvenation of their skin.. When the high priced anti-aging creams do not show any effects anymore, we have a new and innovative way to take care of the skin in a painless way. INJEX Pharma AG is starting in a high margin business on a global scale.
The company has a clear target – to become the worldwide market leader in needle free injection technology. The growth of market capitalization shall confirm our success in the near future. We are planning and we are in preparations to change to a segment with high transparency requirements (General Standard) at the Frankfurt Stock Exchange and to list the company in New York.
http://www.injex.de/newsletterarchiv
Having concentrated on the growth of the company in the past period, we will now - with the news about the Canadian registration and our first contract with an US Partner – move into the next phase and expect to present an interesting news flow to our shareholders.
INJEX Pharma AG and American Healthcare Products Inc. signed an exclusive distributor agreement to market needle-free syringe INJEX 30 in the West Coast States of USA
14:20 17.08.12
DGAP-News: INJEX Pharma AG / Key word(s): Contract
INJEX Pharma AG and American Healthcare Products Inc. signed an
exclusive distributor agreement to market needle-free syringe INJEX 30
in the West Coast States of USA
17.08.2012 / 14:15
---------------------------------------------------------------------
INJEX Pharma AG and American Healthcare Products Inc. signed an exclusive
distributor agreement to market needle-free syringe INJEX 30 in the West
Coast States of USA
INJEX Pharma AG ISIN: DE000A0STYL7
Berlin, 17 August 2012
Berlin - American Healthcare Products Inc., headquartered in California,
has been appointed as the exclusive distributor for USA West Coast states
to market INJEX 30 in Washington State, California, Arizona, Nevada and
Oregon. The agreement, includes a fixed minimum volume of 20,000 INJEX
systems in the first year, was signed and the first delivery of products
will start soon in August.
'We are excited about the partnership with INJEX Pharma AG. With FDA 510K
approval for INJEX 30, we are very much convinced about the market
opportunities in the dental, diabetes and medical markets. INJEX is the
painless injection system and a safe alternative to the traditional needle
syringe and a solution for needle phobics. But above all INJEX is an
expression of the American way of life - basic rights of free choice for
patients - and INJEX - the needle-free injection system is the better
choice,' stated American Healthcare Products Inc. Managing Director Richard
Lim.
In October, American Healthcare Products Inc. will present and highlight
the INJEX 30 system and the needle-free treatments at the Annual Show of
the American Dental Association (ADA) to the American dentists.
'We are focused on our network opportunities and immediate market approach.
It's Time to market - we have the sales and marketing strategy in the
exclusive states prepared, the logistics built up and our long term
partners and customers integrated,' added Mr. Richard Lim.
'Together with American Healthcare Products Inc., we have a strong sales
and marketing partner, which has been established in the market,
experienced and has a first class network of institutions, associations and
clinics. This is fundamental for the sales opportunities and we are looking
forward to a successful market entry with our new partner in the US
market,' remarks Mr. Andy Rösch, CEO of INJEX Pharma AG.
Contact:
Andy Rösch
CEO
INJEX Pharma AG
Buckower Damm 114
12349 Berlin
Tel.: 0049-30-53096768
andy.roesch@injex.com
www.injex.com
Sylwin Grinman
Managing Director
INJEX Pharma USA
1922 NE 119 RD
North Miami Beach - FL - 33181
USA
Tel.: +1 786 512 196 3
sylwin@injex.com
End of Corporate News
---------------------------------------------------------------------
17.08.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
http://www.dgap.de/news/corporate/injex-pharma-and-american-healthcare-products-inc-signed-exclusive-distributor-agreement-market-needlefree-syringe-injex-the-west-coast-states-usa_42269_729684.htm
Hi-Tech Plastics for the vial produced by Bayer
http://www.bayer.de/
http://www.makrolon.com/bms/db-rsc/makroloncmsr6.nsf/id/home_en
Source of the following media: http://www.azom.com/news.aspx?newsID=13652
Bayer MaterialScience Demonstrate Makrolon Polycarbonate Usage in Medical Applications
Published on September 9, 2008 at 10:15 PM
Bayer MaterialScience’s Makrolon® polycarbonate is ideal for use in medical applications, where global trends are driving demand for plastics and materials with superior properties.
INJEX system – a needle-free system INJEX™
“Global trends - such as the preference for self-medication, minimally-invasive treatment and surgery, and emerging areas such as genetics and biotechnology – are driving demand for increasingly innovative medical products,” noted Dr. Markus Steilemann, Vice President of Consumer Products & Medical, for Bayer MaterialScience’s Polycarbonates Business Unit in Asia Pacific.
“Because of the stringent requirements set by the medical industry for such applications, Makrolon®’s ability to withstand high heat and impact, as well as it transparent and aesthetic appeal, make it the material of choice for an extremely versatile range of medical applications,” he explained. Makrolon® can be sterilised with superheated steam, high-energy radiation, or ethylene oxide. It can also be sterilised by laser without discolouring or turning yellow - a problem common to other plastics. All Bayer’s materials used in medical technology comply with US-Pharmacopeia standard Class VI and ISO 10993-1.
“In China, Bayer MaterialScience’s extensive experience collaborating with medical device manufacturers globally, coupled with our local presence and technical support, ensure that we are in a good position to support the needs of medical device manufacturers in China,” Dr. Steilemann said. Citing the example of how Bayer MaterialScience can help its customers ensure better time-to-market for their products, Dr Steilemann explained: “We are able to provide binding assurances regarding the consistency of the relevant formulations and the stability of supply, as well as (the US) FDA-maintained quality of our material. This means that the regulatory approval time needed for goods produced in Asia can be decreased.”
At the MEDTEC 2008 exhibition in Shanghai, the company showcased injection-molded micro forceps which comprise eight moving components made with Makrolon® Rx 2530. The forceps measure only a few millimetres in length and width, and Makrolon® ’s excellent mechanical properties, outstanding strength, stiffness and toughness, together with its good photoconductivity, make the highly-transparent polycarbonate ideal for precise medical use.
Another exhibit featured was a needle-free system called INJEX™ that allows injections to be self-administered painlessly. With the INJEX™ system, drugs are injected into the skin through pressure-resistant ampoules when high air pressure is applied briefly. The INJEX™ system is made with Makrolon® Rx1805, and benefits from the material’s resistance to gamma-ray sterilization and to stress cracking, as well as its superior transparency.
In addition, Bayer’s experts demonstrated Makrolon®’s ability to withstand tough conditions during sterilisation.
Commitment to China’s medical device manufacturing industry
Dr Steilemann said Bayer MaterialSciences aims to strengthen its ability to provide highly-tailored solutions to local customers in the medical industry. “In addition to ensuring the reliable supply of high quality product, we also are placing significant emphasis on supporting our customers with technical solutions in colour selection and measurement,” said Dr. Steilemann. “With our extensive medical and technological expertise, our local teams can anticipate our customers' needs and are able to offer specific professional advice and expertise, whether in supporting material trials or regulatory documentation,” he said.
Supported by local production capacity at the Bayer Integrated Site Shanghai, and technical support at Bayer’s Polymer Reseach and Development Center ( PRDC) in Shanghai- Bayer brings its rich global experience with customers around the world to a local level, to ensure that local needs are always met. The company’s Colour Competence Centre (CCC) and Customer Interface Centre (CIC) provide platforms where customers can take full advantage of Bayer’s professional solutions, including optimising production process and products as well as colour-selection and measurement.
“Domestic customers are eager and well-prepared to grow their businesses and markets, and we are ready by their side when it comes to materials and services concerning medical grade polycarbonates. We are confident that our efforts, together with local government support, will ensure a bright future for China’s medical device market,” concluded Dr. Steilemann.
The total needle-free delivery market is expected to grow rapidly
http://www.visiongain.com/Press_Release/141/The-total-needle-free-delivery-market-is-expected-to-grow-rapidly-as-more-opportunities-arise-from-new-technology-and-emerging-economies
What would you prefer?
beauty treatment with needle:
Homepages of Injex in different countries:
www.injex.de
www.injex.com
www.injex.us
www.injex.info
www.injex.com.au/
www.safeinject.com.br
www.injex.cc
www.injex.co.il
www.injex.co.il/ru
www.injex.kr/index.php
www.injexuk.com
The innovative method for reducing wrinkles gently and completely needle-free
is a milestone. I think this will come out on top...
Video will be available in english next week:
http://www.injex.com/fight-wrinkles-injex
German Video:
http://www.injex.de/shireen-bei-beauty-trends